^
    2d
    Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL (clinicaltrials.gov)
    P2, N=50, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • lenalidomide • Inokai (orelabrutinib)
    4d
    LOXO-BCL-20001: Study of Oral LOXO-338 in Patients With Advanced Blood Cancers (clinicaltrials.gov)
    P1, N=316, Active, not recruiting, Eli Lilly and Company | Trial completion date: Dec 2025 --> Jun 2026
    Trial completion date
    |
    Chr t(11;14)
    |
    Jaypirca (pirtobrutinib) • FCN-338
    4d
    MZL-IIT-O: Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL (clinicaltrials.gov)
    P2, N=30, Recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    Inokai (orelabrutinib)
    7d
    Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, Fudan University | Recruiting --> Active, not recruiting | Trial completion date: Sep 2028 --> Sep 2027 | Trial primary completion date: Sep 2027 --> Aug 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Inokai (orelabrutinib)
    7d
    Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Mayo Clinic | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date • Adverse events
    7d
    Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (clinicaltrials.gov)
    P2, N=60, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Jan 2028 --> Mar 2029 | Trial primary completion date: Feb 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    cyclophosphamide • fludarabine IV • busulfan • cyclosporin A microemulsion • Grafapex (treosulfan) • Neupogen (filgrastim)
    7d
    Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (clinicaltrials.gov)
    P2, N=22, Terminated, University of Ulm | Phase classification: P=N/A --> P2
    Phase classification
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Keytruda (pembrolizumab) • Rituxan (rituximab) • Truxima (rituximab-abbs)
    8d
    Small B-cell lymphoma highly suspicious for splenic marginal zone lymphoma with MYD88 L265P mutation and MYC copy-number gain presenting as severe autoimmune hemolytic anemia: a case report with literature review. (PubMed, Front Immunol)
    This case, together with a review of the literature, suggests that such "clinically indolent but genetically high-risk" SMZL-like lymphomas may carry a non-negligible risk of progression and transformation and therefore require close longitudinal monitoring. Further accumulation of similar cases and molecular data is needed to clarify the prognostic and biological impact of MYD88 and MYC alterations in this setting.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    8d
    Primary Dural Diffuse Large B-Cell Lymphoma: A Report of a Rare Case and Review of the Literature. (PubMed, Cureus)
    The patient received six cycles of rituximab-based chemotherapy (R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), followed by cranial radiotherapy, and achieved complete remission after 12 months. While MZL subtypes typically behave indolently, DLBCL variants require aggressive multimodal therapy. This report highlights the importance of histopathologic confirmation in all dural-based lesions and demonstrates that early multidisciplinary management, including surgery, rituximab-based chemotherapy, and radiotherapy, can result in sustained remission even in highly aggressive forms.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • CD79A (CD79a Molecule) • MME (Membrane Metalloendopeptidase)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone
    11d
    PRO00037171: CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Medical College of Wisconsin | Trial completion date: Jun 2028 --> Feb 2029 | Trial primary completion date: Jun 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    CAR-20/19-T Cells
    14d
    A Study of APG-3288 in Relapsed/Refractory Blood Cancers (clinicaltrials.gov)
    P1, N=180, Not yet recruiting, Ascentage Pharma Group Inc.
    New P1 trial
    17d
    MAZ-01: Zanubritnib and anti-MAG neuropathy (2025-523091-23-00)
    P1/2, N=50, Not yet recruiting, Azienda Ospedaliera di Padova
    New P1/2 trial
    |
    Brukinsa (zanubrutinib)